LB Pharmaceuticals Inc Common Stock
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 1 clinical trial for the treatment of bipolar I depression; and in … Read more
LB Pharmaceuticals Inc Common Stock (LBRX) - Total Liabilities
Latest total liabilities as of September 2025: $10.53 Million USD
Based on the latest financial reports, LB Pharmaceuticals Inc Common Stock (LBRX) has total liabilities worth $10.53 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
LB Pharmaceuticals Inc Common Stock - Total Liabilities Trend (2022–2024)
This chart illustrates how LB Pharmaceuticals Inc Common Stock's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
LB Pharmaceuticals Inc Common Stock Competitors by Total Liabilities
The table below lists competitors of LB Pharmaceuticals Inc Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Tinybeans Group Limited
PINK:TNYYF
|
USA | $1.81 Million |
|
Badger Capital Corp
V:YVR-P
|
Canada | CA$102.24K |
|
INTERPARFUMS
STU:I8P
|
Germany | €324.52 Million |
|
BROWN NON VTG-B
BE:BF5B
|
Germany | €4.74 Billion |
|
LENZING
BE:LEN
|
Germany | €3.57 Billion |
Liability Composition Analysis (2022–2024)
This chart breaks down LB Pharmaceuticals Inc Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 47.60 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.03 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.03 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how LB Pharmaceuticals Inc Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for LB Pharmaceuticals Inc Common Stock (2022–2024)
The table below shows the annual total liabilities of LB Pharmaceuticals Inc Common Stock from 2022 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $128.09 Million | +59.85% |
| 2023-12-31 | $80.13 Million | +59.29% |
| 2022-12-31 | $50.30 Million | -- |